Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. (NASDAQ: ASRT) generates a steady flow of news related to its role as a pharmaceutical company focused on oncology, neurology, and pain management. This news page aggregates company-issued press releases and other coverage so readers can follow developments that affect Assertio’s business and ASRT stock.
Recent communications emphasize Assertio’s commercial execution around Rolvedon, a long-acting G-CSF indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in certain adult cancer patients, and SYMPAZAN, an oral film formulation of clobazam approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. News items include clinical trial readouts, such as a phase 1 study of same-day dosing of Rolvedon with chemotherapy, and real-world evidence studies describing how Sympazan is used in daily clinical practice.
Investors and observers will also find updates on financial results, guidance ranges, and strategic priorities, including portfolio focus on core growth assets, responses to generic competition for products like Indocin, and steps to streamline the corporate structure. Assertio’s announcements cover quarterly net product sales, adjusted EBITDA, and commentary on commercial performance, alongside information about investor conference participation and earnings calls.
Governance and capital markets developments appear in the news flow as well, such as leadership transitions at the chief executive level, the appointment of a President and Chief Operating Officer, and the implementation of a 1-for-15 reverse stock split to support Nasdaq listing compliance. Subsequent confirmation from Nasdaq that Assertio regained compliance with listing requirements is also communicated through press releases.
By reviewing the ASRT news feed, readers can track clinical data publications, operational updates, executive changes, supply and licensing agreements, and listing status disclosures that help explain how Assertio is executing its stated strategy in oncology, neurology, and pain management.
Assertio (Nasdaq: ASRT) and Garda reached a mutual agreement to delay the launch of the previously announced tender offer to May 14, 2026. Assertio reaffirmed its amended and restated merger agreement with Garda to be acquired for $21.80 per share, totaling $153.2 million in cash. The company expects to file a Schedule 14D-9 in connection with the tender offer on May 14, 2026. Assertio also delayed the launch of the previously announced tender offer for all outstanding Convertible Senior Notes until May 14, 2026.
Assertio (Nasdaq: ASRT) and Garda mutually agreed to postpone the commencement of Garda's previously announced tender offer to acquire all outstanding Assertio shares to May 8, 2026. The Garda agreement values Assertio at $21.80 per share, or $153.2 million in total cash consideration. Assertio expects to file a Schedule 14D-9 on May 8, 2026. The company also postponed the tender offer for all outstanding Convertible Senior Notes until May 8, 2026.
Assertio (Nasdaq: ASRT) and Garda Therapeutics amended their merger agreement on May 1, 2026, raising the all-cash tender offer to $21.80 per share (≈$153.2M total). The revised price is a 21.1% increase from Garda’s prior offer and a 63.1% premium to the March 20, 2026 unaffected price. The transaction is expected to close in Q2 2026, requires a majority tender and will delist Assertio from Nasdaq upon completion. Assertio withdrew 2026 guidance and will file required SEC disclosures, including a Schedule 14D-9 and Form 8-K.
Assertio (Nasdaq: ASRT) and Garda agreed to extend the deadline to commence Garda’s tender offer to May 4, 2026. Assertio previously entered a definitive agreement for Garda to acquire all outstanding shares at $18.00 per share for total cash consideration of $125.1 million, plus a contingent value right. The Garda Agreement contains a 20-day window-shop allowing Assertio to solicit superior bids; if the board terminates for a superior bid during that period, a reduced breakup fee applies.
Assertio (Nasdaq: ASRT) said Garda Therapeutics intends to commence a tender offer to acquire all outstanding shares on April 29, 2026, after a 20-day window-shop period. The agreed purchase price is $18.00 per share, totaling $125.1 million in cash, plus a contingent value right. The window-shop permits Assertio to solicit superior bids; if the Board accepts a superior proposal and terminates the Garda Agreement, a reduced breakup fee would apply.
Cosette Pharmaceuticals closed an agreement to acquire U.S. sales and distribution rights for seven branded products from Assertio (Nasdaq: ASRT), adding a portfolio with $48.9 million in 2025 net sales. The deal includes SYMPAZAN® oral film, which establishes a Neurology rare disease footprint and carries patent protection through 2040.
The portfolio also includes INDOCIN®, SPRIX®, ZIPSOR®, CAMBIA®, and OTREXUP® (OTREXUP was discontinued in Aug 2025). A transition period will move manufacturing, supply, quality, pharmacovigilance, and regulatory responsibilities to Cosette.
Assertio (Nasdaq: ASRT) agreed to be acquired by Garda Therapeutics for $18 per share in cash (total $125.1 million) plus a contingent value right (CVR) tied to Sprix milestones. The offer represents a 34.6% premium to the unaffected price and includes a 20-day window-shop period. Assertio also sold non-Rolvedon assets to Cosette for $35 million upfront plus earnouts. Closing is expected in Q2 2026, subject to a majority tender and customary conditions; Assertio stock will be delisted after closing.
Assertio (Nasdaq: ASRT) reported Q4 and full-year 2025 results and issued 2026 guidance. Full-year 2025 net product sales were $117.1M and Adjusted EBITDA was $22.7M. Rolvedon sales totaled $68.2M in 2025. Cash and short-term investments were $63.4M at year-end. For 2026 the company expects Net Product Sales $110M–$125M and Adjusted EBITDA $28M–$40M.
Q4 trends included a Rolvedon quarter‑end sell‑in that reduced Q4 Rolvedon sales and working capital variability into early 2026.
Assertio Holdings (Nasdaq: ASRT) will report fourth quarter and full year 2025 financial results on Monday, March 16, 2026 after market close.
Management will host a live webcast and earnings call at 4:30 p.m. Eastern Time; telephone dial-in and a webcast replay (available ~two hours after the call) are provided on the company investor website.
Assertio Holdings (NASDAQ: ASRT) announced that as of January 12, 2026 Nasdaq has determined the company has regained compliance with all applicable listing requirements.
Nasdaq confirmed Assertio met the Minimum Bid Price Rule requiring a minimum bid of $1.00 per share for at least ten consecutive days, and that the matter is now closed. Management said compliance was achieved following the December 2025 reverse stock-split, while preserving capital allocation flexibility.